Exact Sciences — Jan 12, 2025 release

investorrelations@exactsciences.com 608-535-8659   Media Contact: Steph Spanos Exact Sciences Corp. sspanos@exactsciences.com 608-556-4380   For Immediate Release   Exact Sciences Announces Preliminary Fourth Quarter 2024 Results Highlighted announcements: • Expects total fourth quarter revenue of $713 million, an increase of 10% compared to the fourth quarter of 2023, with Screening revenue of $553 million and Precision Oncology revenue of $161 million • Anticipates total full-year 2024 revenue of $2.76 billion, an increase of 10% compared to full-year 2023 • Plans to launch three new cancer tests in 2025: Cologuard Plus TM , next-generation colorectal cancer screening test, Oncodetect TM , molecular residual disease test, and Cancerguard TM , multi-cancer screening test MADISON, Wis. , January 12, 2025 -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report revenue of $713 million for the fourth quarter ended December 31, 2024. "The Exact Sciences team delivered strong results to finish 2024, setting us up for sustained growth and profitability in the years to come," said Kevin Conroy, chairman and CEO. "We look forward to expanding our impact as the platform supporting Cologuard ® and Oncotype DX ® powers three new cancer diagnostics launching in 2025, enabling Exact Sciences to advance cancer prevention, early detection, and personalized treatment." Preliminary, Unaudited Fourth Quarter 2